272 related articles for article (PubMed ID: 36717900)
21. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
Front Genet; 2023; 14():1039813. PubMed ID: 36755568
[TBL] [Abstract][Full Text] [Related]
22. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
23. A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder.
Feng H; Deng Z; Huang Y; Liu Z; Ruan Y; Wang T; Liu J
Front Immunol; 2023; 14():1219209. PubMed ID: 37662947
[TBL] [Abstract][Full Text] [Related]
24. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer.
Sha S; Si L; Wu X; Chen Y; Xiong H; Xu Y; Liu W; Mei H; Wang T; Li M
Front Immunol; 2022; 13():922780. PubMed ID: 35979353
[TBL] [Abstract][Full Text] [Related]
25. Identification of cuproptosis-related lncRNAs for prognosis and immunotherapy in glioma.
Wang L; Li Y; Wang Y; Li J; Sun Y; Chen J; Wang Z
J Cell Mol Med; 2022 Dec; 26(23):5820-5831. PubMed ID: 36317420
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
27. Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation.
Liu Z; Zhu F; Zhang P; Qian B; Liu W; Xiao Y; Chen N; He Q; Xiao J
Front Genet; 2022; 13():1074981. PubMed ID: 36506302
[No Abstract] [Full Text] [Related]
28. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer.
Huang Y; Yin D; Wu L
Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436
[TBL] [Abstract][Full Text] [Related]
29. A novel cuproptosis-related gene signature to predict prognosis in Glioma.
Zhang M; Liu X; Wang D; Ruan X; Wang P; Liu L; Xue Y
BMC Cancer; 2023 Mar; 23(1):237. PubMed ID: 36915038
[TBL] [Abstract][Full Text] [Related]
30. Integrated machine learning and bioinformatic analyses used to construct a copper-induced cell death-related classifier for prognosis and immunotherapeutic response of hepatocellular carcinoma patients.
Zhao S; Chen S; Liu W; Wei S; Wu X; Cui D; Jiang L; Chen S; Wang J
Front Pharmacol; 2023; 14():1188725. PubMed ID: 37266152
[No Abstract] [Full Text] [Related]
31. Consensus Clustering and Survival-Related Genes of Cuproptosis in Cutaneous Melanoma.
Qin W; Gan F; Jike Y; Jiang M; Li A
Mediators Inflamm; 2023; 2023():3615688. PubMed ID: 36891324
[TBL] [Abstract][Full Text] [Related]
32. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis-Mediated Patterns Characterized by Distinct Tumor Microenvironment and Predicted the Immunotherapy Response for Gastric Cancer.
Wang XX; Deng SZ; Wu LH; Liu QQ; Zheng G; Du K; Dou QY; Zheng J; Zhang HM
ACS Omega; 2023 Mar; 8(12):10851-10862. PubMed ID: 37008098
[TBL] [Abstract][Full Text] [Related]
35. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
36. Prediction model of clinical prognosis and immunotherapy efficacy of gastric cancer based on level of expression of cuproptosis-related genes.
Zhao B; Wu W; Liang L; Cai X; Chen Y; Tang W
Heliyon; 2023 Aug; 9(8):e19035. PubMed ID: 37636385
[TBL] [Abstract][Full Text] [Related]
37. A novel Cuprotosis-related signature predicts the prognosis and selects personal treatments for melanoma based on bioinformatics analysis.
Hu B; Hounye AH; Wang Z; Qi M; Zhang J
Front Oncol; 2023; 13():1108128. PubMed ID: 36824136
[TBL] [Abstract][Full Text] [Related]
38. Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer.
Zhang H; Liu J; Zheng Z
PeerJ; 2023; 11():e15088. PubMed ID: 37041979
[TBL] [Abstract][Full Text] [Related]
39. Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma.
Wu G; Hu Q; Chen H; He M; Ma H; Zhou L; Xu K; Ren H; Qi J
Front Oncol; 2023; 13():1127768. PubMed ID: 37007124
[TBL] [Abstract][Full Text] [Related]
40. Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma.
Shen Y; Li D; Liang Q; Yang M; Pan Y; Li H
Front Immunol; 2022; 13():1029092. PubMed ID: 36733399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]